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Abstract
Background: A single low dose (0.25 mg/kg) of primaquine is recommended as a gametocytocide in combination
with artemisinin-based combination therapies for Plasmodium falciparum but its effect on post-treatment gametocyte
circulation and infectiousness to mosquitoes has not been quantified.
Methods: In this randomised, double-blind, placebo-controlled trial, 360 asymptomatic parasitaemic children aged 2-15
years were enrolled and assigned to receive: artemether-lumefantrine (AL) and a dose of placebo; AL and a 0.25 mg/kg
primaquine dose; or AL and a 0.40 mg/kg primaquine dose. On days 0, 2, 3, 7, 10 and 14, gametocytes were detected
and quantified by microscopy, Pfs25 mRNA quantitative nucleic acid sequence based amplification (QT-NASBA), and
quantitative reverse-transcriptase PCR (qRT-PCR). For a subset of participants, pre- and post-treatment infectiousness
was assessed by mosquito feeding assays on days -1, 3, 7, 10 and 14.
Results: Both primaquine arms had lower gametocyte prevalences after day 3 compared to the placebo arm,
regardless of gametocyte detection method. The mean (95 % confidence interval) number of days to gametocyte
clearance in children with patent gametocytes on day 0 (N = 150) was 19.7 (14.6 – 24.8), 7.7 (6.3 – 9.1) and 8.2
(6.7 – 9.6) for the AL-placebo, the 0.25 mg/kg primaquine dose and the 0.40 mg/kg primaquine dose arms,
respectively. While 38.0 % (30/79) of selected gametocytaemic individuals were infectious before treatment, only
1/251 participant, from the AL-placebo group, infected mosquitoes after treatment.
Conclusions: We observed similar gametocyte clearance rates after 0.25 and 0.40 mg/kg primaquine doses.
Infectivity to mosquitoes after AL was very low and absent in primaquine arms.
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Background
Infectiousness to malaria vectors depends on the presence
of sexual stage parasites, gametocytes, in the peripheral
blood and is essential to sustain transmission in endemic
areas [1]. Shortening the duration of gametocyte circula-
tion reduces the probability of parasite spread and might,
therefore, facilitate control. Artemisinin-based combin-
ation therapy (ACT) is universally adopted as first-line
treatment for clinical falciparum malaria [2], effectively
clears asexual parasites and immature gametocytes, and is
associated with lower post-treatment infectivity based on
membrane feeding assays compared to other antimalarials
[3]. Mature gametocytes, however, persist after ACT
in microscopic or submicroscopic concentrations and
residual transmission has been reported following
sulphadoxine-pyrimethamine in combination with artesu-
nate [4, 5], dihydroartemisinin-piperaquine [4, 6] and
artemether-lumefantrine (AL) [4, 6].
Primaquine, tafenoquine and methylene blue radically
clear mature gametocytes with primaquine being the
only one commonly used as antimalarial [7]. The World
Health Organization recommends a single low dose
(0.25 mg/kg) as a gametocytocide in combination with
ACT for Plasmodium falciparum malaria in elimination
and artemisinin resistance containment scenarios [8].
However, wide-scale adoption of this recommendation is
limited by safety concerns [9], despite evidence that a
higher dose, 0.40 mg/kg, is associated with only minor
haematological changes in G6PD normal children [10].
Furthermore, the effect of the 0.25 mg/kg dose in clearing
gametocytes or preventing transmission after currently
used ACT regimens has not been formally assessed. A
dose-finding study in Uganda suggested a 0.40 mg/kg dose
is as efficacious in clearing gametocytes as the previously
recommended dose of 0.75 mg/kg [10], which has been
associated with haemolysis [11]. At present, only mosquito
feeding assays can truly determine the lowest efficacious
dose of primaquine for preventing transmission [12].
Here, we compare gametocyte dynamics after AL alone
or in combination with 0.25 mg/kg or 0.40 mg/kg prima-
quine dose in children with asymptomatic falciparum infec-
tion. We selected asymptomatic parasite carriers since
these contribute considerably to the infectious reservoir for
malaria [13, 14] and malaria elimination and artemisinin
resistance containment strategies will need to involve the
targeting of asymptomatic malaria infections [15]. For a
subset of participants, post-treatment infectiousness was
determined by mosquito membrane feeding experiments.
Methods
Role of the funding source
Authors had full access to the trial data. Funders had no
role in study design, data collection, analysis, interpretation
and decision to publish study findings.
Study design
For this randomised, double-blind, placebo-controlled
trial, participants were recruited between September 2013
and October 2014 from Balonghin, district of Saponé, an
area with seasonal malaria in Burkina Faso [16].
Eligible individuals were asymptomatic children aged 2
to 15 years, weighing 10 kilos or more, with normal
glucose-6-phosphate dehydrogenase (G6PD) activity based
on BinaxNOW rapid diagnostic test (Alere Inc., Waltham,
MA, USA) and carrying patent P. falciparum asexual para-
sites or gametocytes. Initially, individuals were recruited
regardless of microscopy gametocyte status (Study Phase
A). Since no mosquito infections were detected (0/106
participants), the parasitological criterion for inclusion in
infectiousness assessments was modified to include only
children with patent gametocytes at screening, regardless of
their asexual parasite count, to maximize pre-treatment in-
fectivity (Study Phase B). Exclusion criteria were: haemoglo-
bin level at screening lower than 8 g/dL, fever or history of
fever in the last 24 hours, evidence of severe illness, known
allergy to study medications, antimalarials taken in the last
48 hours, primaquine use in the last four weeks, blood
transfusion in the last 90 days, and non-falciparum mal-
aria infection at screening. Overall, 360 children were
enrolled: 210 in Study Phase A (inclusion criterion:
asexual parasite density 1,000 - 200,000 parasites/μL) and
150 participants in Study Phase B (inclusion criterion:
presence of gametocytes by microscopy) (Fig. 1).
Ethics, consent and permissions
This clinical trial was conducted in accordance with Good
Clinical Practice guidelines, and was registered with Clini-
calTrials.gov (number NCT01935882). Ethical clearance
was obtained from the London School of Hygiene and
Tropical Medicine ethics committee (reference number
6274), and the Comité d’Ethique pour la Recherche en
Santé (Ministère de la Santé du Burkina Faso; reference
number 2012-10-78). Written informed consent was
obtained from parents or guardians, and assent, from
children 12-years old or older. The original protocol for
the clinical trial (Additional file 1) and the supporting
CONSORT checklist (Additional file 2) are provided as
supporting information.
Randomisation and masking
Children were enrolled by the study clinician and subse-
quently randomly allocated by the study pharmacist,
with equal probabilities, to three treatment arms: (1) AL
as standard six-dose regimen in combination with a sin-
gle dose of placebo; (2) AL and a single 0.25 mg/kg
primaquine dose; and (3) AL and a single 0.40 mg/kg
primaquine dose.
Treatment assignment was stratified by gender, and
sealed envelopes in block sizes of six (three study arms
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Fig. 1 (See legend on next page.)
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and two membrane feeding assays schedules [days 3 and
10 or 7 and 14 after treatment initiation]) were used.
After the first 143 children were recruited, mosquito
feeding experiments were amended: gametocytaemic
children were randomised to have feeding assays on days -1
(one day before treatment initiation) and 7 or 3 and 7.
Treatment concealment was achieved by the addition
of a syrup, which masked the colour and taste of prima-
quine and placebo. Participants, investigators, and staff
who were not involved in study drug administration
were blinded to study arm allocation.
Procedures
AL (Coartem®; Novartis Pharma, Basel, Switzerland) was
administered as half a tablet (20 mg of artemether and
120 mg of lumefantrine) per 5 kg of body weight in a
six-dose regimen over three days. Primaquine doses were
prepared as previously described [10] and given with the
fifth dose (day 2) of AL. All treatment doses were adminis-
tered under supervision and with fatty food (biscuits) to
ensure adequate absorption [17] and minimise the risk of
gastro-intestinal side effects. If a child vomited within
30 minutes after a study medication was given, the treat-
ment was re-administered.
Participants were asked to return to the study clinic on
days 0, 1, 2, 3, 7, 10 and 14. On day 0 (day of enrolment),
AL administration was initiated. On each follow-up day,
study subjects were examined and, except on day 1,
had a blood slide prepared to detect malaria parasites
and their haemoglobin levels quantified by Hemocue
photometer (HemoCue AB, Angelholm, Sweden). Smears
were screened for asexual stage parasites and gametocytes,
and double-read. Biochemistry and full blood count as-
sessments were performed on days 0, 3 and 7 on venous
samples.
Finger-prick-blood samples (50 μL) were collected on
all visits, except on day 1, stored in 250 μL of RNAprotect®
cell reagent (Qiagen), and used for gametocyte detection
and quantification: quantitative nucleic acid sequence
based amplification (QT-NASBA) [18] was performed
for samples collected on days 0 and 7; and quantitative
reverse-transcriptase PCR (qRT-PCR), which allows
better quantification [19], was used to estimate gameto-
cyte densities in all available samples for individuals with
patent gametocytes on day 0. Briefly, total nucleic acids
(NA) were extracted using a MagNAPure LC automatic
extractor (Total Nucleic Acid Isolation Kit – High
Performance, Roche Applied Science). QT-NASBA was
performed directly on total NA samples as described [18],
with a minor change in the KCl concentration used: 60
instead of 80 mM. For gametocyte quantification by
qRT-PCR, the remaining genomic human and parasite
DNA were first removed with the RQ1 DNaseI Digest
Kit (Promega), then cDNA was synthesized with the High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems); from cDNA samples, the Pfs25 sequence was
amplified using primers described by Wampfler et al [19],
GoTaq® qPCR Master Mix (Promega), and CFX96™
Real-Time PCR Detection System (BIO-RAD), using
the standard cycling program as described in the manufac-
turer’s instructions. Amplification was set to continue for
40 cycles and the cut-off for positivity was set at assigned
gametocyte density of more than 0.02 gametocytes per μL,
determined by a dilution series of mature stage V in vitro
produced gametocytes (NF54 strain).
A subset of recruited children was invited to partici-
pate in membrane feeding assays [20] at two time-points
(Fig. 1), with the number of participants being dictated
by the availability of mosquitoes. For each experiment,
venous blood was taken and offered to 60 or more
locally-reared female Anopheles gambiae mosquitoes.
Fully fed mosquitoes were selected, kept on glucose at
27–29 °C and dissected seven days later. Midguts were
examined for the presence of oocysts.
Primary and secondary endpoints
The primary efficacy endpoint was gametocyte clearance
time (i.e. number of days to undetectable gametocyte
levels) in the 0.25 mg/kg primaquine arm compared to
the 0.40 mg/kg primaquine arm. The primary safety end-
point was maximal fall in haemoglobin levels during
follow-up. Secondary efficacy endpoints were: gameto-
cyte prevalence on days 3, 7, 10 and 14, and proportion
of mosquitoes developing infection and their oocyst
counts in feeding assays performed after treatment ad-
ministration. Secondary safety endpoints included: num-
ber of participants requiring blood transfusion, maximal
percentage decrease in haemoglobin concentration, pro-
portion of participants with haemoglobin levels below
5 g/dL and number of serious adverse events.
Sample size
Sample size calculations were based on non-inferiority
of 0.25 mg/kg versus 0.40 mg/kg primaquine dose. For
the gametocyte clearance endpoint, the non-inferiority
margin was 2.5 days [21]. If mean clearance time was
(See figure on previous page.)
Fig. 1 Clinical trial profile. a Study Phase where the presence of asexual parasites (1,000 - 200,000 parasites/μL) at screening was an inclusion
criterion (initial 143 and final 67 participants). b Study Phase where children with patent gametocytes, regardless of their asexual parasite count,
at screening were eligible (150 participants). Participants were considered to have a complete follow-up, if they had a total of seven follow-up
visits (days 0, 1, 2, 3, 7, 10, 14). AL artemether-lumefantrine, PQ primaquine
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6.3 days [10] in both arms, with a standard deviation of
3, then 40 subjects per arm would give over 90 % power
at the one sided 0.025 level. For QT-NASBA-determined
gametocyte prevalence on day 7, the non-inferiority mar-
gin was 12 %. If prevalence in both arms was 10.6 %
[10], then 120 subjects per arm would give over 80 %
power at the one sided 0.025 level. The number of feed-
ing experiments and mosquitoes used in each assay were
limited by logistical considerations and were not based
on sample size calculations.
Statistical analysis
Stata 12.0 (Stata Corporation, College Station, TX, USA)
and SAS 9.3 (SAS Institute, Cary, NC, USA) were used for
statistical analysis. The mean time to gametocyte clearance
was estimated for each treatment arm using a non-linear
model [21] (Additional file 3); qRT-PCR data from children
with patent gametocytes on day 0 were used (N = 150). For
the 0.25 mg/kg primaquine dose, a 95 % confidence interval
(CI) for the difference with the 0.40 mg/kg dose was calcu-
lated. The non-linear model was also used to assess super-
iority of the primaquine arms over the placebo group.
Gametocyte prevalences on different visit days were com-
pared between study arms by χ2 or Fisher’s exact test. Non-
parametric tests (Mann-Whitney and Kruskal-Wallis) were
used to compare parasite levels among different study
groups. To quantify the effect of primaquine on transmis-
sion, post-treatment mosquito infection rates were
compared between treatment arms. The maximal fall in
haemoglobin levels measured by Hemocue photometer was
presented as mean (95 % CI) per study arm; Student’s t-test
was used for pair-wise comparisons.
Results
We screened 2,176 (877 in Study Phase A and 1,299 in
Study Phase B) and enrolled 360 children (Fig. 1). Twenty
participants were enrolled despite having < 1,000 asexual
parasites/μL and therefore not fulfilling all enrolment cri-
teria but were retained in the analysis (Additional file 3).
The median (interquartile range [IQR]) age at enrolment
was eight (five to ten) years (Table 1). Median (IQR) asex-
ual stage parasites concentration at enrolment was 1,824.5
(520–5,041) parasites/μL and was similar among individ-
uals receiving different treatment regimens.
Gametocyte prevalence determined by microscopy was
not significantly different between study arms at enrol-
ment, although during Study Phase A it was higher in
the 0.25 mg/kg primaquine arm (32.0 %) compared to the
AL-placebo and the 0.40 mg/kg primaquine arms (17.7 and
20.5 %, respectively). Both primaquine arms had lower
microscopically-detectable gametocyte prevalence on
days 7, 10 and 14, but not on days 2 and 3, compared
to the AL-placebo group (Table 2). Similar results were
obtained when only children with gametocytes on day 0
were included in this comparison (Additional file 3:
Table S1).
Table 1 Study population
AL only AL + 0.25 mg/kg PQ AL + 0.40 mg/kg PQ
Asymptomatic parasite carriers (Study Phase A)
Female (%) 51.6 52.0 53.4
Age (years) 7.5 (4 – 10) 8 (5 – 10) 8 (4 – 10)
Haemoglobin (g/dL) at enrolmenta 10.8 (10.2 – 11.4) 11.3 (10.7 – 11.9) 11.7 (11.2 – 12.2)
Asexual parasite levels at enrolment (parasites/μL; Microscopy) 2,972.5 (1,147 – 6,865) 2,503 (939 – 5,798) 3,339 (874 – 7,358)
Gametocyte prevalence (%) at enrolment (Microscopy) 17.7 32.0 20.5
Gametocyte prevalence (%) at enrolment (QT-NASBA) 96.4 92.9 85.5
Asymptomatic gametocyte carriers (Study Phase B)
Female (%) 43.1 46.0 42.9
Age (years) 8 (5 – 11) 7 (6 – 11) 8 (6 – 11)
Haemoglobin (g/dL) at enrolmenta 11.4 (11.1 – 11.8) 11.7 (11.4 – 12.1) 11.5 (11.1 – 11.9)
Asexual parasite levels at enrolment (parasites/μL; Microscopy) 488 (226 – 1,670) 957 (248 – 3,004) 908.5 (198 – 2,297)
Gametocyte prevalence (%) at screening (Microscopy) 100 100 100
Gametocyte prevalence (%) at enrolment (Microscopy) 69.4 55.3 83.3
Gametocyte prevalence (%) at enrolment (QT-NASBA) 95.9 93.7 100.0
Gametocyte levels at enrolment (parasites/μL)b 17.3 (7.2 - 45.1) 18.6 (7.8 - 75.3) 16.6 (7.2 - 40.0)
Means and 95 % confidence intervals are presented for haemoglobin levels at enrolment; medians and interquartile ranges are presented for parasite levels
(asexual or sexual stages) and age. Study Phase A = presence of asexual parasites (1,000 - 200,000 parasites/μl) at screening as an inclusion criterion; Study Phase
B = presence of patent gametocytes at screening as an inclusion criterion
AL artemether-lumefantrine, PQ primaquine
aMeasured by Hemocue photometer; similar values observed with full blood count assessment using venous samples
bQuantified by qRT-PCR (only children with patent gametocytes on day 0 [N = 150] were included [100/150 were enrolled during Study Phase B]; see Methods)
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Table 2 Gametocyte carriage during follow-up
Study Phase A (asymptomatic parasite carriers) AL AL + 0.25
mg/kg PQ
AL + 0.40
mg/kg PQ
P-values P-values
% (n/N) % (n/N) % (n/N) (AL vs.AL + 0.25
mg/kg PQ)
(AL vs.AL + 0.40
mg/kg PQ)
Gametocyte prevalence by microscopy
Day 0 17.7 (11/62) 32.0 (24/75) 20.5 (15/73) 0.08 0.83
Day 2 12.9 (8/62) 16.4 (12/73) 13.7 (10/73) 0.63 1.00
Day 3 9.8 (6/61) 22.9 (16/70) 14.3 (10/70) 0.06 0.59
Day 7 6.7 (4/60) 4.2 (3/72) 0.0 (0/71) 0.70 0.04
Day 10 3.3 (2/60) 1.4 (1/71) 0.0 (0/71) 0.60 0.21
Day 14 0.0 (0/58) 0.0 (0/73) 0.0 (0/71) - -
Gametocyte prevalence by Pfs25 QT-NASBA
Day 0 96.4 (54/56) 92.9 (65/70) 85.5 (53/62) 0.46 0.06
Day 7 46.3 (25/54) 20.3 (14/69) 16.4 (11/67) 0.003 0.001
Study Phase B (patent gametocyte carriers
at screening)
AL AL + 0.25
mg/kg PQ
AL + 0.40
mg/kg PQ
P-values P-values
% (n/N) % (n/N) % (n/N) (AL vs.AL + 0.25
mg/kg PQ)
(AL vs.AL + 0.40
mg/kg PQ)
Gametocyte prevalence by microscopy
Day 0 69.4 (34/49) 55.3 (26/47) 83.3 (40/48) 0.21 0.15
Day 2 34.7 (17/49) 20.4 (9/44) 28.9 (13/45) 0.17 0.66
Day 3 28.6 (14/49) 10.9 (5/46) 15.6 (7/45) 0.04 0.15
Day 7 20.4 (10/49) 6.4 (3/47) 6.7 (3/45) 0.07 0.07
Day 10 17.4 (8/46) 4.3 (2/47) 0.0 (0/44) 0.05 0.006
Day 14 13.6 (6/44) 0.0 (0/40) 0.0 (0/38) 0.03 0.03
Gametocyte prevalence by Pfs25 QT-NASBA
Day 0 95.9 (47/49) 93.7 (45/48) 100.0 (46/46) 0.68 0.50
Day 7 55.1 (27/49) 20.4 (10/49) 17.0 (8/47) 0.001 <0.001
Only patent gametocyte carriers at enrolment AL AL + 0.25
mg/kg PQ
AL + 0.40
mg/kg PQ
P-values P-values
% (n/N) % (n/N) % (n/N) (AL vs.AL + 0.25
mg/kg PQ)
(AL vs.AL + 0.40
mg/kg PQ)
Gametocyte prevalence by Pfs25 qRT-PCR
Day 0 95.6 (43/45) 98.0 (48/49) 98.0 (49/50) 0.60 0.60
Day 2 93.2 (41/44) 87.5 (42/48) 90.4 (47/52) 0.49 0.72
Day 3 88.4 (38/43) 75.5 (37/49) 92.2 (48/52) 0.18 0.72
Day 7 66.7 (28/42) 34.0 (17/50) 27.8 (15/54) 0.003 <0.001
Day 10 65.8 (27/41) 28.6 (14/49) 20.7 (11/53) 0.001 <0.001
Day 14 42.5 (17/40) 10.2 (5/49) 16.7 (9/54) 0.001 0.01
Mean (95 % CI) Mean (95 % CI) Mean (95 % CI)
AUC gametocyte densities over time
(in gametocytes μL-1 days)b
14.7 (5.5 – 24.0) 5.5 (1.1 – 10.0) 5.6 (2.1 – 9.1) - -
Gametocyte clearance time (in days) 19.7 (14.6 – 24.8) 7.7 (6.3 – 9.1) 8.2 (6.7 – 9.6) - -
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Molecular detection of gametocytes
Gametocyte prevalences determined by Pfs25 mRNA
QT-NASBA were considerably higher than by microscopy
(Table 2). On day 7, QT-NASBA-determined gametocyte
prevalence was 50.5 % in the AL-placebo arm, 20.3 % in the
0.25 mg/kg primaquine arm (P < 0.001, versus control) and
16.7 % in the 0.40 mg/kg primaquine arm (P < 0.001, versus
control; P = 0.50, versus 0.25 mg/kg primaquine dose).
Gametocyte prevalences and densities measured by
qRT-PCR for children with microscopically detectable
gametocytes on day 0 are presented in Fig. 2. Gametocyte
levels in gametocyte-positive visits did not differ between
treatment arms on days 0, 2, 3 and 14; on days 7 and 10,
the 0.40 mg/kg primaquine arm had lower gametocyte
levels compared to the placebo group (Additional file 3:
Table S2). Gametocyte densities were similar in primaquine
arms throughout the follow-up, as gametocyte clearance
rates. Children receiving either dose carried sexual stage
parasites for a shorter time compared to the AL only arm
(19.7 [14.6 – 24.8], 7.7 [6.3 – 9.1] and 8.2 [6.7 – 9.6] days
[mean and 95 % CI] to gametocyte clearance for the AL-
placebo, the 0.25 mg/kg primaquine and the 0.40 mg/kg
primaquine arms, respectively; Table 2).
Infectiousness to mosquitoes
In Study Phase A, when individuals were recruited re-
gardless of gametocytaemia by microscopy, 106 children
participated in membrane feeding experiments on days 3
(N = 54), 7 (N = 52), 10 (N = 54) and 14 (N = 52); during
this Study Phase, no mosquitoes developed infection
(Table 3). In Study Phase B, 149 individuals with patent
gametocytes at screening participated in feeding experi-
ments prior to treatment (N = 79) and on days 3 (N = 70;
19, 23 and 28 in the AL-placebo, the 0.25 mg/kg prima-
quine and the 0.40 mg/kg primaquine arms, respectively)
and 7 (N = 144; 49, 49 and 46 in the AL-placebo, the
0.25 mg/kg primaquine and the 0.40 mg/kg primaquine
arms, respectively). On average, 45.3 (range 25 - 94)
mosquitoes were dissected per assay. Of the experiments
conducted prior to treatment, 38.0 % (30/79) resulted
Table 2 Gametocyte carriage during follow-up (Continued)
P-values P-values
AL vs. AL + 0.25
mg/kg PQ
AL vs. AL + 0.40
mg/kg PQ
AL + 0.25
mg/kg PQ vs.
AL + 0.40
mg/kg PQ
(AL vs.AL + 0.25
mg/kg PQ)
(AL vs.AL + 0.40
mg/kg PQ)
Difference in gametocyte clearance
time (in days)
12.0 (6.7 – 17.3) 11.5 (6.2 – 16.8) -0.5 (- 2.5 – 1.6) <0.001 <0.001
Gametocyte prevalences, clearance times and area under the curve (AUC) of gametocyte distributions over time are presented. Gametocyte clearance time: the
rate with which malaria sexual stage parasites were cleared was estimated for children with patent gametocytes on day 0; qRT-PCR data were used (N = 150; see
Additional file 3). Gametocyte prevalences were similar in primaquine study arms throughout the follow-up (all P-values > 0.05), except on day 0 (microscopy-based
detection; P = 0.004) during Study Phase B
AL artemether-lumefantrine, PQ primaquine
a50 children from Study Phase A and 100 from Study phase B
bOnly qRT-PCR measurements on days 3, 7, 10 and 14 for children with qRT-PCR data on all these days are included
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Fig. 2 Gametocyte prevalences (a) and densities (b) measured by qRT-PCR in children with patent gametocytes on day 0. 95 % confidence
intervals are presented in (a). Samples were considered to be gametocyte negative if assigned levels were lower than 0.02 gametocytes per μL.
AL = artemether-lumefantrine; 0.25 mg/kg = 0.25 mg/kg primaquine arm; 0.40 mg/kg = 0.40 mg/kg primaquine arm
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in ≥ 1 infected mosquito. In these 30 infectious feeds,
the median proportion of infected mosquitoes was
20.0 % (IQR 8.0 – 39.0) and median oocyst count per in-
fected mosquito was 5 (IQR 2 – 15). Only one individual
infected mosquitoes following treatment, in the AL only
arm and infected 4/46 mosquitoes on day 7; this partici-
pant, who was also infectious before treatment adminis-
tration (18/48 infected mosquitoes), had submicroscopic
gametocytaemia at the time of feeding on day 7.
Adverse events and haematological changes in G6PD
normal children
A total of 57 mild and moderate adverse events were re-
corded; eight (seven mild, one moderate), occurring in
three, one and four individuals assigned to the AL-
placebo, the 0.25 mg/kg primaquine and the 0.40 mg/kg
primaquine arms, respectively, were considered to be
possibly related to study participation (Additional file 3:
Table S3). For five children who vomited on days 0 or 1,
study drug was re-administered. No serious adverse events
were observed.
At enrolment, haemoglobin levels did not differ between
treatment arms (Table 1). One child had 6 g/dL on day 0,
but this was most likely due to measurement error: on day
2, haemoglobin concentration was 10.9 g/dL. Median
(IQR) uncorrected reticulocyte percentage at enrolment
was 2.0 % (1.5 – 2.6). The average maximal fall in haemo-
globin levels for children with measurements on all visits
(227/360) was larger (P = 0.006), in absolute value, in the
0.40 mg/kg primaquine arm, -1.21 (95 % CI, -1.45 to -0.97,
N = 76) g/dL, compared to the placebo arm, -0.71 (95 %
CI, -0.98 to -0.44, N = 72). The haemoglobin drop for
participants receiving the 0.25 mg/kg primaquine dose
was -0.96 (95 % CI, -1.18 to -0.73, N = 79; P = 0.16 and
0.12, versus control and 0.40 mg/kg primaquine arms,
respectively). Similar results were obtained when con-
sidering maximal percentage drop (Additional file 3:
Table S4). The lowest haemoglobin values relative to
baseline were observed on days 3 and 7 (Fig. 3). A total
of 35 children (9/113 [8.0 %], 12/125 [9.6 %] and 14/122
[11.5 %] in the AL-placebo, the 0.25 mg/kg primaquine
and the 0.40 mg/kg primaquine arms, respectively) had a
haemoglobin drop of 2 or more g/dL (Additional file 3:
Table S5): in 2, one in each primaquine arm, haemoglobin
fell more than 4 g/dL and levels recovered before
follow-up was completed. On days 1 and 2, three children
reported haemoglobinuria. No child had haemoglobin
levels < 5 g/dL, and no blood transfusions were required.
Renal and liver laboratory abnormalities were detected in
four and seven children, respectively (Additional file 3:
Table S6).
Discussion
Since 2012, the WHO recommends a single 0.25 mg/kg
primaquine dose as gametocytocide but this dosage had
never been formally assessed for gametocyte clearance
after ACT. In this study, we recruited asymptomatic
parasitaemic children, a group that is believed to con-
tribute significantly to transmission in endemic areas
[13] and would potentially be given low dose primaquine
if used in future community chemotherapy campaigns.
We showed that individuals receiving a 0.25 mg/kg
primaquine dose in combination with AL had similar
gametocyte clearance time compared to children in the
0.40 mg/kg primaquine arm. Both regimens were associ-
ated with significantly shorter post-treatment gameto-
cyte circulation compared to the ACT partner drug
alone. In the subset of participants who had their infect-
ivity quantified by feeding experiments, infectiousness
was effectively reduced after treatment in all arms. Our
Table 3 Mosquito feeding assays
AL only AL + 0.25 mg/kg PQ AL + 0.40 mg/kg PQ
Study phase A
Number of mosquitoes infected/dissected (proportion)
Follow-up day
3 0/755 (0) 0/816 (0) 0/862 (0)
7 0/781 (0) 0/777 (0) 0/767 (0)
10 0/822 (0) 0/848 (0) 0/890 (0)
14 0/855 (0) 0/890 (0) 0/841 (0)
Study phase B
Number of mosquitoes infected/dissected (proportion)
Follow-up day
One day before treatment 207/1402 (0.15) 54/1195 (0.05) 80/897 (0.09)
3 0/863 (0) 0/1053 (0) 0/1281 (0)
7 4/2104 (0.002) 0/2179 (0) 0/2016 (0)
AL artemether-lumefantrine; PQ primaquine
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observations suggest that (1), on the basis of gametocyte
carriage, the primaquine dose of 0.25 mg/kg is as effect-
ive as the previously evaluated dose, 0.40 mg/kg; and (2)
gametocytaemia is not a good predictor of post-
treatment infectivity [12]: infectivity is very low after AL
and not detected after AL-primaquine.
Previous trials on low dose primaquine’s transmission-
reducing properties have assessed efficacy based on gam-
etocyte carriage [10]. However, the non-linear relationship
between gametocyte levels and mosquito infection rates
[22] during experimental infections suggests that reduc-
tions in numbers of circulating gametocytes might not be
directly translated into changes in transmission potential.
Additionally, primaquine might have an impact on infec-
tiousness before sexual stage parasites clearance is ob-
served [12]. Pfs25 mRNA transcripts are more abundantly
present in female gametocytes [23] and may also be de-
tected in non-infectious gametocytes [24]. It was recently
hypothesized that male gametocytes might be more
sensitive to 8-aminoquinolines in vivo [25] and, since
they represent a smaller fraction of the total gametocyte
population compared to female gametocytes [26], their
clearance will only minimally influence gametocytaemia
by Pfs25 mRNA-based quantification methods but sig-
nificantly affect infectiousness [27]. Thus, estimating
the effect of primaquine on transmission requires direct
assessment of infectivity. In this trial, we quantified in-
fectiousness for 255 individuals and 22,894 dissected
mosquitoes and adapted our study design to maximise
discriminative power by enriching our study population for
individuals with microscopically-detectable gametocytes.
We observed that 38.0 % of gametocytaemic individuals
infected mosquitoes before treatment. This is within the
normal range of infectivity in patent gametocyte carriers
[28], although considerably higher infection rates have
been reported [22, 29]. After treatment, only one child in-
fected mosquitoes, suggesting that transmissibility was
substantially reduced by AL [3]. Low infectivity after AL
alone made it impossible to detect an added value of
primaquine in this context. The almost complete absence
of infected mosquitoes post-treatment contrasts with
the limited efficacy of artemisinin derivatives against
mature gametocytes, and could be related to lumefan-
trine, that inhibits male gametocyte exflagellation and
reduces oocyst numbers in vitro [30]. Factors intrinsic
to these infections (e.g. gametocyte sex ratios) or to the
host (e.g. transmission-reducing immunity) could also have
contributed to this low infectiousness. Another explanation
is that membrane feeding experiments, which in general
underestimate infectiousness compared to skin feeding
assays [28], might not have been sensitive enough to
detect very low infectivity. The successful detection of
pre-treatment infectiousness, however, suggests that
low sensitivity cannot fully explain our findings. Only a
few studies (summarised in Additional file 3: Table S7)
assessed the effect of AL on transmission: similar to our
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observations, in The Gambia, post-treatment gametocyte
carriage was observed, but mosquito infections were not
detected [3]. In contrast, in Kenya, transmission was ob-
served after AL [6] and clonally complex infections were
detected by PCR in infected mosquito guts.
Determining the true impact of primaquine on malaria
infectivity should be high on the malaria elimination
agenda. Larger clinical studies with appropriate sample
sizes to test efficacy outcomes involving infectiousness
reduction are necessary. These studies may also deter-
mine the optimum timing of primaquine administration.
In our study, primaquine was administered on the last
day of AL use, to follow the same treatment procedures
as a previous dose-finding trial in Uganda, although
there are logistical advantages to administering prima-
quine with the first supervised dose of AL. Ideally, these
studies will include symptomatic and asymptomatic mal-
aria infections to demonstrate the efficacy of primaquine
in all infections that contribute to the human infectious
reservoir for malaria. These studies will be logistically
complex and need to consider all factors that influence
infectiousness as they might also influence efficacy esti-
mates: (1) membrane feeding assays underestimate in-
fectivity compared to direct skin feeding assays and
consequently low level post-treatment infectivity might
be misclassified as non-infectiousness when using this
artificial system; (2) the number of mosquitoes used in
each assay might not represent the number of mosquito
bites an infectious individual would receive in natural
settings (especially acknowledging as this is a single time
point assessment), and binary outcomes (e.g. “infectious”
versus “not-infectious”) might be less relevant than
within-individual changes in mosquito infection rates;
(3) baseline infectivity will depend on the inclusion cri-
teria and although recruiting individuals with high gam-
etocyte densities would maximize the power to observe
changes in infectiousness with treatment, these individ-
uals might not be representative of an “average” infected
person. As duration and intensity of infectiousness are
likely to depend on host age and transmission setting,
individuals from different ages and study sites, repre-
senting a wide spectrum of endemicities, would need to
be recruited.
Primaquine-induced haemolysis in individuals with
G6PD deficiency is a concern for control programs and
one major reason why this drug is not widely used in
Africa. Here, a rapid diagnostic test was used to exclude
individuals with this condition. No cases of severe haem-
olysis were observed, corroborating previous observations
made in symptomatic children with normal G6PD activity
receiving a single 0.40 mg/kg primaquine dose [10]. How-
ever, contrary to this previous trial undertaken in Uganda,
children receiving 0.40 mg/kg primaquine in this study
had larger haemoglobin drops compared to the placebo
group, suggesting that mild haemolysis might have oc-
curred. While our study provides detailed haemato-
logical assessment after primaquine administration in
G6PD normal non-anaemic children with asymptomatic
falciparum infections, G6PD deficiency could lead to
greater haemoglobin drops and studies recruiting G6PD
deficient individuals are necessary.
Conclusions
The ultimate goal of using primaquine in falciparum
malaria in conjunction with ACT is to minimise post-
treatment malaria transmission, reduce the transmission
of artemisinin-resistant parasites and accelerate attempts
to eliminate malaria [31]. Although mathematical models
have been developed to estimate the potential impact of
this drug on population-level transmission [32], its effect
on infectiousness needs to be quantified. In this study,
children receiving 0.40 mg/kg or 0.25 mg/kg primaquine
doses cleared gametocytes with similar rates; both treat-
ment regimens reduced gametocyte carriage compared to
ACT alone. Feeding assays, however, indicate that infec-
tiousness is considerably reduced by AL alone, suggesting
that the benefit of adding primaquine to first-line antima-
larials is influenced by partner drug.
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